Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.

BACKGROUND: Some patients with chronic obstructive pulmonary disease (COPD) respond to corticosteroid therapy. Whether these patients have different airway pathology from other COPD patients is unclear. We tested the hypothesis that response to prednisolone is related to the presence of eosinophilic...

Full description

Bibliographic Details
Main Authors: Brightling, C, Monteiro, W, Ward, R, Parker, D, Morgan, MD, Wardlaw, A, Pavord, I
Format: Journal article
Language:English
Published: 2000
_version_ 1797072889496731648
author Brightling, C
Monteiro, W
Ward, R
Parker, D
Morgan, MD
Wardlaw, A
Pavord, I
author_facet Brightling, C
Monteiro, W
Ward, R
Parker, D
Morgan, MD
Wardlaw, A
Pavord, I
author_sort Brightling, C
collection OXFORD
description BACKGROUND: Some patients with chronic obstructive pulmonary disease (COPD) respond to corticosteroid therapy. Whether these patients have different airway pathology from other COPD patients is unclear. We tested the hypothesis that response to prednisolone is related to the presence of eosinophilic airway inflammation. METHODS: We did a randomised, double-blind, crossover trial. Patients who had COPD treated with bronchodilators only were assigned placebo and 30 mg prednisolone daily for 2 weeks each, in a random order, separated by a 4-week washout period. Before and after each treatment period, we assessed patients with spirometry, symptom scores, the chronic respiratory disease questionnaire (CRQ), incremental shuttle walk test, and induced sputum. Analysis was done by intention to treat. FINDINGS: 83 patients were recruited, of whom 67 were randomised. The geometric mean sputum eosinophil count fell significantly after prednisolone (from 2.4% to 0.4%; mean difference six-fold [95% CI 3.1-11.4]) but not after placebo. Other sputum cell counts did not change. After stratification into tertiles by baseline eosinophil count, postbronchodilator forced expiratory volume in 1 s (FEV1) and total scores on the CRQ improved progressively after prednisolone from the lowest to the highest eosinophilic tertile, compared with placebo. The mean change in postbronchodilator FEV1, total CRQ score, and shuttle walk distance with prednisolone compared with placebo in the highest tertile was 0.19 L (0.06-0.32), 0.62 (0.31-0.93), and 20 m (5-35), respectively. INTERPRETATION: Our findings suggest that eosinophilic airway inflammation contributes to airflow obstruction and symptoms in some patients with COPD and that the short-term effects of prednisolone are due to modification of this feature of the inflammatory response. The possibility that sputum eosinophilia identifies a subgroup of patients who particularly respond to long-term treatment with inhaled corticosteroids should be investigated.
first_indexed 2024-03-06T23:14:12Z
format Journal article
id oxford-uuid:66897710-7d31-4a9e-8f9d-1659b0db3c5b
institution University of Oxford
language English
last_indexed 2024-03-06T23:14:12Z
publishDate 2000
record_format dspace
spelling oxford-uuid:66897710-7d31-4a9e-8f9d-1659b0db3c5b2022-03-26T18:32:36ZSputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:66897710-7d31-4a9e-8f9d-1659b0db3c5bEnglishSymplectic Elements at Oxford2000Brightling, CMonteiro, WWard, RParker, DMorgan, MDWardlaw, APavord, IBACKGROUND: Some patients with chronic obstructive pulmonary disease (COPD) respond to corticosteroid therapy. Whether these patients have different airway pathology from other COPD patients is unclear. We tested the hypothesis that response to prednisolone is related to the presence of eosinophilic airway inflammation. METHODS: We did a randomised, double-blind, crossover trial. Patients who had COPD treated with bronchodilators only were assigned placebo and 30 mg prednisolone daily for 2 weeks each, in a random order, separated by a 4-week washout period. Before and after each treatment period, we assessed patients with spirometry, symptom scores, the chronic respiratory disease questionnaire (CRQ), incremental shuttle walk test, and induced sputum. Analysis was done by intention to treat. FINDINGS: 83 patients were recruited, of whom 67 were randomised. The geometric mean sputum eosinophil count fell significantly after prednisolone (from 2.4% to 0.4%; mean difference six-fold [95% CI 3.1-11.4]) but not after placebo. Other sputum cell counts did not change. After stratification into tertiles by baseline eosinophil count, postbronchodilator forced expiratory volume in 1 s (FEV1) and total scores on the CRQ improved progressively after prednisolone from the lowest to the highest eosinophilic tertile, compared with placebo. The mean change in postbronchodilator FEV1, total CRQ score, and shuttle walk distance with prednisolone compared with placebo in the highest tertile was 0.19 L (0.06-0.32), 0.62 (0.31-0.93), and 20 m (5-35), respectively. INTERPRETATION: Our findings suggest that eosinophilic airway inflammation contributes to airflow obstruction and symptoms in some patients with COPD and that the short-term effects of prednisolone are due to modification of this feature of the inflammatory response. The possibility that sputum eosinophilia identifies a subgroup of patients who particularly respond to long-term treatment with inhaled corticosteroids should be investigated.
spellingShingle Brightling, C
Monteiro, W
Ward, R
Parker, D
Morgan, MD
Wardlaw, A
Pavord, I
Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.
title Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.
title_full Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.
title_fullStr Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.
title_full_unstemmed Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.
title_short Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.
title_sort sputum eosinophilia and short term response to prednisolone in chronic obstructive pulmonary disease a randomised controlled trial
work_keys_str_mv AT brightlingc sputumeosinophiliaandshorttermresponsetoprednisoloneinchronicobstructivepulmonarydiseasearandomisedcontrolledtrial
AT monteirow sputumeosinophiliaandshorttermresponsetoprednisoloneinchronicobstructivepulmonarydiseasearandomisedcontrolledtrial
AT wardr sputumeosinophiliaandshorttermresponsetoprednisoloneinchronicobstructivepulmonarydiseasearandomisedcontrolledtrial
AT parkerd sputumeosinophiliaandshorttermresponsetoprednisoloneinchronicobstructivepulmonarydiseasearandomisedcontrolledtrial
AT morganmd sputumeosinophiliaandshorttermresponsetoprednisoloneinchronicobstructivepulmonarydiseasearandomisedcontrolledtrial
AT wardlawa sputumeosinophiliaandshorttermresponsetoprednisoloneinchronicobstructivepulmonarydiseasearandomisedcontrolledtrial
AT pavordi sputumeosinophiliaandshorttermresponsetoprednisoloneinchronicobstructivepulmonarydiseasearandomisedcontrolledtrial